Previous studies of human microbiome may be biased in favour of Global North
A new study has suggested that previous global research into the human microbiome is heavily biased in favour of wealthy countries such as the US and UK.
List view / Grid view
A new study has suggested that previous global research into the human microbiome is heavily biased in favour of wealthy countries such as the US and UK.
New pre-clinical research from the Université Laval Faculty of Medicine and CHU de Québec–Université Laval Research Centre showed genetically mutating human cells could avoid Alzheimer’s disease.
New research by the University of California, San Diego could provide a much simpler way to repair disease-causing mutations in RNA.
Researchers have shown that engineered bacterial genes coding for sodium ion channels could lead to novel gene therapies for electrical heart diseases.
A new CAR T-cell therapy for B-cell cancers promises to reduce the antigen escape currently found in therapies that only target CD19.
Scientists at Georgia State University have developed an intranasal influenza vaccine using a new combination of nanoparticles for improved defence against flu strains.
Scientists in Japan have developed a credible heart cell model for arrhythmogenic cardiomyopathy and observed a positive response in the condition using PKP2 gene therapy.
Researchers have found that extracellular vimentin facilitates SARS-CoV-2 entry into human cells, presenting a new target.
Researchers have found that genes in small organisms, known to extend lifespan, could also impact ageing in humans.
In mice, researchers have shown that δ-valerobetaine plays a role in neurocognitive ability, making the metabolite a target for age-related memory loss.
Researchers have developed a new drug delivery system using virus-like particles to successfully transport gene-editing proteins in pre-clinical studies.
Representing a breakthrough in better understanding how tau proteins cause neurodegenerative disease, scientists have mapped the tau interactome.
Using cryo-electron microscopy, researchers have completed the world’s first molecular analysis of the SARS-CoV-2 Omicron spike protein.
Janssen's monoclonal antibody CR9114, for the potential treatment of influenza, has been exclusively licensed by Leyden Labs for development and commercialisation.
Research has shown that memory T cells formed following SARS-CoV-2 infection or mRNA vaccination respond to the Omicron variant.